Cytomx Therapeutics Stock Intrinsic Value – CYTOMX THERAPEUTICS Reports 37.1% Revenue Increase for Q1 FY2023
May 26, 2023
Earnings Overview
CYTOMX THERAPEUTICS ($NASDAQ:CTMX) reported total revenue of USD 23.5 million for the first quarter of FY2023, ending on March 31 2023, a 37.1% increase from the same period in the previous year. Net income was reported at USD -3.3 million, a significant improvement from the previous year’s figure of -23.9 million. These results were made public on May 9 2023.
Analysis – Cytomx Therapeutics Stock Intrinsic Value
GoodWhale has conducted a financial analysis of CYTOMX THERAPEUTICS and determined that its fair value is approximately $3.9 per share using our proprietary Valuation Line. Currently, CYTOMX THERAPEUTICS stock is traded at $1.7, which represents an undervaluation of 56.8%. In other words, investors may be able to capitalize on potential long-term gains from investing in the company. In addition to the undervaluation of 56.8%, GoodWhale’s financial analysis of CYTOMX THERAPEUTICS also revealed that the company’s fundamentals are strong. Its revenue growth is on an upward trend, and its operating cash flow is healthy. Moreover, the company has a strong balance sheet with low debt-to-equity ratio. All these factors suggest that CYTOMX THERAPEUTICS may be a good investment option. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Cytomx Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 67.62 | -70.65 | -104.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cytomx Therapeutics. More…
| Operations | Investing | Financing |
| -60.13 | -47.65 | 0.64 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cytomx Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 234.63 | 321.27 | -1.31 |
Key Ratios Snapshot
Some of the financial key ratios for Cytomx Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -4.5% | – | -110.8% |
| FCF Margin | ROE | ROA |
| -90.5% | 54.3% | -20.0% |
Peers
CytomX’s lead product candidate, CX-072, is a CD37-targeting ADC in Phase 1 clinical development for the treatment of hematologic malignancies, solid tumors, and other diseases. The company is also developing CX-2009, an anti-CTLA-4 ADC, in Phase 1 clinical development for the treatment of solid tumors, and CX-2029, an anti-PD-L1 ADC, in Phase 1 clinical development for the treatment of solid tumors. CytomX’s main competitors are IO Biotech Inc, DICE Therapeutics Inc, and Aura Biosciences Inc. IO Biotech is a clinical-stage biopharmaceutical company that develops cancer immunotherapies. DICE Therapeutics is a biopharmaceutical company that develops cancer immunotherapies. Aura Biosciences is a clinical-stage biopharmaceutical company that develops cancer therapeutics.
– IO Biotech Inc ($NASDAQ:IOBT)
Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes small molecule drugs to treat serious unmet medical needs, primarily in oncology. As of 2022, Incyte had a market capitalization of $67.43 million and a return on equity of -20.77%. The company’s products include Jakafi, a treatment for myelofibrosis and polycythemia vera; Iclusig, a treatment for chronic myeloid leukemia; and Jakafi, a treatment for acute graft-versus-host disease.
– DICE Therapeutics Inc ($NASDAQ:DICE)
DICE Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel therapeutics for the treatment of cancer. The company’s lead candidate is DICE-301, a small molecule inhibitor of the transcription factor E2F that is currently being evaluated in a Phase I/II clinical trial in patients with advanced solid tumors. DICE-301 has shown preliminary efficacy in patients with advanced solid tumors, including non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company is also developing DICE-201, a small molecule inhibitor of the transcription factor c-Myc, which is currently in preclinical development.
– Aura Biosciences Inc ($NASDAQ:AURA)
Aura Biosciences Inc is a clinical-stage biopharmaceutical company developing a new class of drugs called tumor-targeted photodynamic therapies (PDTs) for the treatment of solid tumors. PDTs are a type of cancer treatment that uses light to kill cancer cells. The company’s lead product candidate, AU-011, is a PDT that is being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors. Aura Biosciences Inc has a market cap of $365.63M as of 2022 and a Return on Equity of -21.81%. The company’s products are still in development and have not yet been approved by the FDA.
Summary
Investors have reason to be optimistic about CYTOMX THERAPEUTICS, following the first quarter of FY2023 which ended on March 31 2023. Total revenue saw a 37.1% year-over-year increase to USD 23.5 million and net income improved significantly from -23.9 million to -3.3 million. This is a strong indication of the company’s positive financial future, as demonstrated by the impressive earnings report released on May 9 2023.
